Literature DB >> 15466982

Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study.

Jari A Laukkanen1, David E Laaksonen, Leo Niskanen, Eero Pukkala, Anna Hakkarainen, Jukka T Salonen.   

Abstract

OBJECTIVE: Individual components of metabolic syndrome have been linked to an increased risk for prostate cancers. We hypothesized that metabolic syndrome itself could confer an increased risk for incident prostate cancer.
METHODS: The participants were a population-based sample of 1,880 men from eastern Finland without history of cancer or diabetes mellitus at baseline.
RESULTS: The metabolic syndrome (WHO criteria) was present in 357 (19%) of subjects. During an average follow-up of 13 years, a total of 183 cancers occurred, of which 56 were due to prostate cancer. The metabolic syndrome at baseline was related to a 1.9-fold (95% confidence interval, 1.1-3.5) risk of prostate cancer after adjustment for age, alcohol consumption, physical fitness, and energy, fat, fiber, calcium, vitamin E, and alpha-linolenic acid intake. The association between metabolic syndrome and risk of prostate cancer was stronger among overweight and obese men with a body mass index > or = 27 kg/m2 (adjusted relative risk, 3.0; 95% confidence interval, 1.2-7.3) than in lighter men (relative risk, 1.8; 95% confidence interval, 0.7-4.7).
CONCLUSIONS: Middle-aged men with the metabolic syndrome were more likely to develop prostate cancer in this prospective population-based study. This finding suggests that efforts to curb the epidemic of overweight and sedentary lifestyle and the accompanying metabolic syndrome may decrease the risk for prostate cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15466982

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  51 in total

1.  The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.

Authors:  Birgitta Grundmark; Hans Garmo; Massimo Loda; Christer Busch; Lars Holmberg; Björn Zethelius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Marian L Neuhouser; Cathee Till; Alan Kristal; Phyllis Goodman; Ashraful Hoque; Elizabeth A Platz; Ann W Hsing; Demetrius Albanes; Howard L Parnes; Michael Pollak
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

Review 3.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

4.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

Review 5.  The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis.

Authors:  Raxitkumar Jinjuvadia; Suhag Patel; Suthat Liangpunsakul
Journal:  J Clin Gastroenterol       Date:  2014-02       Impact factor: 3.062

6.  Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort.

Authors:  L C Macleod; L J Chery; E Y C Hu; S B Zeliadt; S K Holt; D W Lin; M P Porter; J L Gore; J L Wright
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-03-31       Impact factor: 5.554

7.  Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.

Authors:  Katharine N Sourbeer; Lauren E Howard; Gerald L Andriole; Daniel M Moreira; Ramiro Castro-Santamaria; Stephen J Freedland; Adriana C Vidal
Journal:  BJU Int       Date:  2014-10-20       Impact factor: 5.588

8.  Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.

Authors:  R Asmar; J L Beebe-Dimmer; K Korgavkar; G R Keele; K A Cooney
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-08-21       Impact factor: 5.554

Review 9.  Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis.

Authors:  K Esposito; P Chiodini; A Capuano; G Bellastella; M I Maiorino; E Parretta; A Lenzi; D Giugliano
Journal:  J Endocrinol Invest       Date:  2013-02       Impact factor: 4.256

10.  Midlife metabolic factors and prostate cancer risk in later life.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2017-11-16       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.